Search This Blog

Monday, November 4, 2019

Revance Therapeutics EPS beats by $0.02, misses on revenue

Revance Therapeutics (NASDAQ:RVNC): Q3 GAAP EPS of -$0.96 beats by $0.02.
Revenue of $0.05M (-97.9% Y/Y) misses by $0.37M.
Cash and equivalents of $58.92M
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)